Lv1
100 积分 2026-05-03 加入
C42-36 Ocrelizumab and the Hidden Pattern of Organizing Pneumonia
58分钟前
已完结
The Lung Microbiome in Carcinogenesis and Immunotherapy Treatment
2个月前
已完结
PDL1 and IDO ‐2 Immunohistochemistry in Bronchoalveolar Lavage Versus Bronchoscopic Biopsy of Non‐Small Cell Lung Cancer
2个月前
已完结
Tertiary lymphoid structures in anticancer immunity
3个月前
已完结
Future perspectives and challenges for identification and recognition of clinically significant cancer biomarkers
3个月前
已关闭
Serum iron element: A novel biomarker for predicting PD-1 immunotherapy efficacy
3个月前
已完结
The Lung Microbiome in Carcinogenesis and Immunotherapy Treatment
3个月前
已完结
Role of Yin Yang 1 (YY1) on microenvironment, signaling pathways, and epigenetics in lung cancer
3个月前
已关闭
Strategies to optimize duration of immunotherapy in advanced NSCLC: Current evidence and future directions
4个月前
已完结
Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers
4个月前
已完结
皖公网安备34019202002308
